Transit Therapeutics focuses on protein-free trans-splicing of pre-mRNA with technology out of MIT/Harvard and UC Berkeley/Arc Institute and a focus on CNS and other target organs. We also own genomic integration IP and are currently actively discussing partnerships with Pharma and are seeking Seed funding to build a small lab and execute on a first partnership. We have already been accepted into LabCentral in Cambridge, MA and recently won a Golden Ticket sponsored by Daiichi Sankyo.